ACCESS Newswire

Jupiter Wellness, Inc.

15.7.2021 14:32:32 CEST | ACCESS Newswire | Press release

Share
Jupiter Wellness Announces Appointment of Dr. Andy Goren to Scientific Advisory Board

JUPITER, FL / ACCESSWIRE / July 15, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that Dr Andy Goren has been appointed to its Scientific Advisory Board.

Dr. Andy Goren has more than twenty years of experience in clinical research, development, and commercialization of breakthrough therapeutics and diagnostics. Among his list of many firsts in dermatology, Dr. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid-test for predicting Minoxidil response in Androgenetic Alopecia.

Dr. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy-induced alopecia, excessive hair shedding, female sexual dysfunction, and COVID-19. His latest research involves the use of anti-androgen therapy for the treatment of COVID-19 that was performed in conjunction with the Brazilian Government.

Dr. Goren is the President and Chief Medical Officer of Applied Biology, Irvine, CA. He is External Medical Advisor and a Co-Researcher, Trichology Unit, Ramon y Cajal Hospital, Madrid, Spain, a Visiting Professor of Dermatology, Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, a Medical Doctor at the Skin & Cosmetic Research Dept., Shanghai Skin Disease Hospital, Shanghai, China, and a Visiting Medical Doctor, Department of Dermatology and Venereology, L.T.M. Medical College Sion, Mumbai, India. Clinical Research Director at Samel Hospital, Manaus, Brazil. Dr. Goren has published dozens of peer-reviewed original medical research papers. He is an honorary as well as an ordinary member of several dermatology societies worldwide as well as a regular lecturer at dermatology congresses around the world.

"We are delighted to welcome Dr. Goren to our Scientific Advisory Board" stated Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness. "We have already established an important collaboration with him and his colleagues for our clinical programs in eczema, burns, and actinic keratosis. Andy's expertise in dermatology and widespread access to clinics worldwide will help progress the development of our skin products and provide us access to patients through his many affiliations with large dermatological hospitals around the world. More importantly, he has a unique understanding of the translation of scientific data into commercial products".

About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skincare therapeutics and treatments. The Company's product pipeline of enhanced skincare therapeutics focuses on the endocannabinoid system to address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com.

For additional information, please visit www.jupiterwellness.com. The Company's public filings can be found at www.Sec.gov.

Safe Harbor Statement
To the extent, any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that is based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors relating to the company's industry, its operations and results of operations, and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@JupiterWellness.com

SOURCE: Jupiter Wellness, Inc.



View source version on accesswire.com:
https://www.accesswire.com/655589/Jupiter-Wellness-Announces-Appointment-of-Dr-Andy-Goren-to-Scientific-Advisory-Board

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release

NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release

Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye